Načítá se...
State of the art in anti-cancer mAbs
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today,...
Uloženo v:
| Vydáno v: | J Biomed Sci |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5319201/ https://ncbi.nlm.nih.gov/pubmed/28219375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12929-016-0311-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|